Monoclonal antibodies (Mabs) are a potential key component for the treatment of cancer, because of their specificity and multiple effector functions. Hybridoma technology and progress in genetic ...

From 31 centers, 166 patients were entered. Of this intent-to-treat group, 48% responded. With a median follow-up duration of 11.8 months, the projected median time to progression for responders is 13 ...

In therapeutic applications, monoclonal antibodies (mAbs) provide highly precise targeting of pathological cells and reduced side effects in treating disease. Experimental mice are widely used models ...

Scientists have developed a new chimeric antibody that suppresses malignant cancers in dogs, showing promise for safe and effective treatment of intractable cancers. Similar to our aging society, dogs ...

In 1975, Georges Köhler and César Milstein, biochemists from the Medical Research Council Laboratory of Molecular Biology, published a paper in Nature about a hybridoma technology that enabled the ...

The "Global Cancer Monoclonal Antibody Partnering Terms and Agreements 2014-2020" report has been added to ResearchAndMarkets.com’s offering. The Global Cancer Monoclonal Antibody Partnering Terms and ...

In Centocor Ortho Biotech, Inc. v. Abbott Laboratories (Feb. 23, 2011), the U.S. Court of Appeals for the Federal Circuit (the Federal Circuit) recently revisited the written description requirement ...

In a recent study published in Cell, researchers described their self-designed chimeric receptor-binding domain (RBD)-dimer vaccine approach to adapt severe acute respiratory syndrome coronavirus 2 ...